Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) Shares Outstanding (Weighted Average) (2019 - 2026)

Alx Oncology Holdings' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $43.0 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 5.62% to $43.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was $43.0 million, a 5.62% increase, with the full-year FY2023 number at $43.0 million, up 5.62% from a year prior.
  • Shares Outstanding (Weighted Average) hit $43.0 million in Q4 2023 for Alx Oncology Holdings, up from $41.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for ALXO hit a ceiling of $43.0 million in Q4 2023 and a floor of $3.1 million in Q3 2019.
  • Historically, Shares Outstanding (Weighted Average) has averaged $28.2 million across 5 years, with a median of $40.2 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): skyrocketed 1174.7% in 2021 and later grew 0.53% in 2023.
  • Tracing ALXO's Shares Outstanding (Weighted Average) over 5 years: stood at $3.1 million in 2019, then skyrocketed by 500.86% to $18.5 million in 2020, then soared by 118.05% to $40.3 million in 2021, then grew by 0.97% to $40.7 million in 2022, then increased by 5.62% to $43.0 million in 2023.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ALXO at $43.0 million in Q4 2023, $41.1 million in Q3 2023, and $40.9 million in Q2 2023.